Phase 1, Randomized Open Label, Multiple Dose, Parallel Study To Assess The Immunogenicity Of Multiple Subcutaneous (sc) Doses Of The Proposed Pegfilgrastim Biosimilar (Pf-06881894) And Us-approved Neulasta (Registered) In Healthy Volunteers

Trial Profile

Phase 1, Randomized Open Label, Multiple Dose, Parallel Study To Assess The Immunogenicity Of Multiple Subcutaneous (sc) Doses Of The Proposed Pegfilgrastim Biosimilar (Pf-06881894) And Us-approved Neulasta (Registered) In Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Febrile neutropenia; Neutropenia
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Jul 2018 Planned End Date changed from 29 Jul 2018 to 25 Jul 2018.
    • 03 Jul 2018 Planned primary completion date changed from 29 Jul 2018 to 25 Jul 2018.
    • 06 Apr 2018 Planned End Date changed from 25 Jun 2018 to 29 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top